Long-Term Follow Up Study of Subjects Previously Administered HMI 102

Plain-language summary

This study aims to provide long-term follow-up for participants who previously received a gene therapy called HMI-102. To take part, participants must have been given HMI-102 in an earlier study and be able to comply with all follow-up procedures. It is a non-phase follow-up study and enrolls by invitation.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Enrolling by invitation

Sponsor

Homology Medicines, Inc

Intervention

HMI-102

Start date

8/19/2020

Estimated completion

12/1/2026

Countries

United States

Related genes

Locations

• Boston, United States
• New York, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Subject was previously administered HMI 102.
* Subject is able to understand the purpose and risks of the study and is willing to provide informed consent.
* Subject is able to comply with all study procedures and long-term follow-up.

Exclusion Criteria:

* Participation in the study is not in the subject's best interest, in the opinion of the Investigator.